MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences [Yahoo! Finance]
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences
MDxHealth announces next phase of collab with University of Oxford [Yahoo! Finance]
Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer
MDxHealth (NASDAQ:MDXH) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $7.00 price target on the stock.